Infliximab biosimilar - LG Life SciencesAlternative Names: LBIM-0101; TNFmab
Latest Information Update: 07 Oct 2013
At a glance
- Originator LG Life Sciences
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 31 Dec 2012 Preclinical development is ongoing in South Korea
- 31 Dec 2008 Preclinical trials in Rheumatoid arthritis in South Korea (Parenteral)